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Background: Mice from the MRL or “superhealing” strain have enhanced repair after acute injury to the skin,
cornea, and heart. We now tested an admixture of the MRL genome and found that it altered the course of muscle
pathology and cardiac function in a chronic disease model of skeletal and cardiac muscle. Mice lacking
γ-sarcoglycan (Sgcg), a dystrophin-associated protein, develop muscular dystrophy and cardiomyopathy similar to
their human counterparts with limb girdle muscular dystrophy. With disruption of the dystrophin complex, the
muscle plasma membrane becomes leaky and muscles develop increased fibrosis.
Methods: MRL/MpJ mice were bred with Sgcg mice, and cardiac function was measured. Muscles were assessed
for fibrosis and membrane leak using measurements of hydroxyproline and Evans blue dye. Quantitative trait locus
mapping was conducted using single nucleotide polymorphisms distinct between the two parental strains.
Results: Introduction of the MRL genome reduced fibrosis but did not alter membrane leak in skeletal muscle of
the Sgcg model. The MRL genome was also associated with improved cardiac function with reversal of depressed
fractional shortening and the left ventricular ejection fraction. We conducted a genome-wide analysis of genetic
modifiers and found that a region on chromosome 2 was associated with cardiac, diaphragm muscle and
abdominal muscle fibrosis.
Conclusions: These data are consistent with a model where the MRL genome acts in a dominant manner to
suppress fibrosis in this chronic disease setting of heart and muscle disease.
Keywords: Cardiomyopathy, Fibrosis, MRL, Muscular dystrophyBackground
Murphy Roths Large (MRL) mice are an inbred mouse
strain noted to have enhanced healing ability. This MRL
strain was initially discovered because of its rapid ability
to heal ear holes [1,2]. The MRL strain’s capacity to rap-
idly recover from injury has been seen for both digit
wounding and corneal scarring [3,4]. The MRL strain
has been reported to reduce scar formation after acute
cardiac injury, including freeze injury and coronary ar-
tery ligation [5,6]. However, other studies have suggested
that larger scale acute cardiac injury cannot be overcome
by the MRL strain’s healing capacity [7-11]. In those* Correspondence: emcnally@uchicago.edu
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distribution, and reproduction in any mediuminjury settings where the MRL background induces more
rapid healing, multiple mechanisms have been impli-
cated to explain this phenomenon including decreased
scar formation, altered inflammatory response, reduced
apoptosis, increased proliferation, improved remodeling
and, in some settings, enhanced stem cell function
[4,6,12-15]. Genetic data support that many different
mechanisms account for enhanced healing since more
than 40 different genetic loci have been associated with
aspects of the healing phenotype [14,16].
The dystrophin complex is composed of membrane-
associated proteins that mediate membrane stability in
heart and skeletal muscle. Mutations that disrupt expres-
sion of dystrophin or its associated proteins the sarco-
glycans proteins cause progressive cardiac and skeletal
muscle degeneration in humans and mouse models. At
the cellular level, the loss of dystrophin or thentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Number of mice analyzed
Trait Genotypes
Fibrosis SgcgD2 SgcgMRL/D2 SgcgMRL/D2, 32wk
Quadriceps 25 124 18
Diaphragm 25 45 10
Heart 27 125 9
Membrane leak SgcgD2 SgcgMRL/D2 SgcgMRL/D2, 32wk
Quadriceps 37 149 15
Gluteus 11 76 15
Triceps 14 110 15
Abdominals 14 74 15
Gastrocnemius/soleus 14 111 15
Central nuclei SgcgD2 SgcgMRL/D2
Quadriceps 6 7
Diaphragm 6 4
Fiber size variability SgcgD2 SgcgMRL/D2
Quadriceps 7 9
Diaphragm 6 4
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brane that is abnormally leaky. Membrane permeability
results in increased intracellular calcium that triggers
proteolysis and necrosis. An inflammatory response also
contributes to muscle degeneration [17]. Muscle con-
traction is thought to provoke submicroscopic disrup-
tion of the sarcolemma, and in the absence of a normal
dystrophin complex, this leads to dysfunction and de-
struction of cardiomyocytes and skeletal myofibers. The
reduction in contractile cells and the presence of fibrotic
scar tissue within the heart led to reduced cardiac con-
tractile function and congestive heart failure.
Mouse models of dystrophin or sarcoglycan mutations
recapitulate the basic pathological defects seen in human
forms of these genetic disorders. Mice lacking γ-
sarcoglycan were engineered by removing the first cod-
ing exon of the Sgcg gene and model muscular dystrophy
[18]. We previously introduced the Sgcg allele into the
DBA/2J genetic background and found that this back-
ground confers a more severe phenotype [19]. The
enhanced severity is seen as increased scar formation,
measured as hydroxyproline (HOP) content because this
modified amino acid is a marker of collagen. In skeletal
muscle, increased Evans blue dye uptake is monitored to
reflect membrane leakiness [20]. Using these assays, we
showed that the DBA/2J genetic background worsened
the disease process [19].
Because of its role in wound healing and the basic
similarities between common forms of cellular injury
and what is seen in muscular dystrophy and cardiomy-
opathy, we introduced the MRL genome into the Sgcg
model. We hypothesized that the indolent pace of cellu-
lar damage in this disorder could be abated by the MRL
background. Sgcg mice were bred to MRL mice to gener-
ate Sgcg mice on a mixed genetic background with 50%
contribution of the MRL strain. This breeding strategy
produced Sgcg mice with 50% genetic background from
the MRL strain and 50% background of the DBA/2J
strain, and these mice are referred to SgcgMRL/D2. We
found that a 50% contribution of the MRL genome
reduced fibrosis in the heart and skeletal muscle, con-
sistent with dominant genetic loci in the MRL back-
ground. Interestingly, the MRL genome did not
consistently reduce membrane leak, suggesting that the
MRL background does not exert its effect on myocyte
membrane stability and instead acts downstream on re-
modeling. SgcgMRL/D2 mice had improved cardiac func-
tion so that they were now similar to wild-type mice.
We conducted a genome-wide scan using informative
polymorphisms and identified a region on chromosome
2 that was associated with fibrosis in cardiac, diaphragm
and abdominal muscles. These data demonstrate that
genes within the MRL background are modifiers for car-
diopulmonary involvement in muscular dystrophy.Methods
Animals
The Sgcg mouse was previously bred for ten generations
into the DBA/2J strain (000671, Jackson Laboratory, Bar
Harbor, ME) [18,19]. MRL/MpJ (000486, Jackson La-
boratory, Bar Harbor, ME) mice were bred to the Sgcg
animals to generate Sgcg+/− F1 mice on a 50% MRL/50%
DBA/2J background. F1 mice were interbred to generate
an F2 cohort. To increase the number of mutant ani-
mals, Sgcg mice from the F2 generation were bred again
to produce additional Sgcg mice from an F3 generation.
All mice were housed in uniform conditions in a single
pathogen-free barrier facility. All animals used in this
study were housed and treated in accordance with the
standards set by the University of Chicago Animal Care
and Use Committee. The number of mice used for histo-
pathological analysis is shown in Table 1.
Mice were sacrificed at either 8 or 32 weeks for ana-
lysis. Muscles were used for either the Evans blue dye
assay or the HOP assay. Dye uptake assays were per-
formed on triceps muscles, gastrocnemius/soleus mus-
cles and gluteus/hamstrings groups of muscles. Dye
uptake was performed on half of each quadriceps
muscle and half of the abdominal muscles since these
muscles are of sufficient size to perform both dye up-
take and fibrosis assays. Hydroxyproline (HOP) assays
were performed on the diaphragm muscle, the cardiac
ventricles isolated as a single unit, half of the abdom-
inal muscles and half of each quadriceps muscle. The
amount of muscle assayed varied with the size of the
muscle and ranged from 30 mg for the diaphragm
muscle to 300 mg for the gluteus/hamstring muscle
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nosus and biceps femoris.
Evans blue dye uptake assay for membrane leak
Evans blue dye (Sigma, E-2129) was performed as
described [19,21]. Evans blue dye (Sigma, E-2129) was
dissolved in phosphate-buffered saline at 10 mg/ml and
injected intraperitoneally at 5 μl/g body weight. Twenty
to 40 h later, the tissues were harvested, finely minced,
weighed and incubated at 55°C in 1 ml formamide for
2 h before spectrophotometric absorbance was measured
at 620 nm [22,23]. Results are reported as absorbance/
mg tissue.
Hydroxyproline assay for fibrosis
The hydroxyproline (HOP) assay was performed as
described [19,21,24]. The tissue was minced, weighed
and hydrolyzed overnight in 2 ml of 6 M hydrochloric
acid at 110°C. Ten μl of this hydrolysate was mixed with
150 μl isopropanol, then 75 μl of 1.4% chloramine-T
(Sigma, St Louis, MO) in citrate buffer and oxidized at
room temperature for 10 min. One ml of a 3:13 solution
of Ehrlich’s reagent (3 g of 4-(dimethylamino) benzalde-
hyde, Sigma, St Louis, MO; 10 ml ethanol; 675 μl sul-
furic acid) to isopropanol was added, mixed and
incubated for 30 min at 55°C followed by extinction
measurement at 558 nm. A standard curve (0–5000 nM,
trans-4-hydroxy-L-proline, Sigma, St Louis, MO) was
included in each assay. Results are reported as nM
HOP/mg tissue.
Immunofluorescence microscopy
Tissues were flash frozen in liquid nitrogen-cooled iso-
pentane and stored at 80°C; 7-μm sections were cut on a
cryostat and fixed to slides in ice-cold 100% methanol.
The following antibodies were used: dystrophin NCL-
DYS2 (Novocastra/Leica), PH3 04–817 (Millipore), CD3
MON1003-1 (Monsanto), caspase 3 (BD Biosciences),
MAC1 BD557395 (BD Biosciences) and eMHC F1.652
(ATCC). The TUNEL kit was from Millipore. Central
nuclei and fiber size variability was determined blinded
to genotype by analyzing ten randomly chosen fields of
40× magnification. Fiber size variability was compared
using each animal’s coefficient of variability (standard
deviation/mean).
Echocardiography
Twelve-week animals were evaluated by echocardiog-
raphy as described [25,26]. Investigators were blinded to
genotype. To avoid the stress associated with conscious
restraint, anesthetized animals were studied. Anesthesia
was induced by 1% isoflurane in a closed chamber
(Ohmeda Fluotec 3; Matrix Medical, Orchard Park, NY)
in 20% O2 delivered through a nose cone. Chest hairswere removed with a topical depilatory agent. Limb leads
were attached for electrocardiogram gating, and the ani-
mals were imaged in the left lateral decubitus position with
a Visual Sonics Vevo 770 machine using a 30-MHz high-
frequency transducer. Body temperature was maintained
using a heated imaging platform and warming lamps.
Anesthesia was variably delivered to maintain heart rates
throughout the procedure at a constant 380–420 beats per
minute. Two-dimensional images were recorded in para-
sternal long- and short-axis projections, with guided M-
mode recordings at the midventricular level in both views.
LV cavity size and wall thickness were measured in at least
three beats from each projection and averaged. LV wall
thickness, interventricular septum (IVS) and posterior wall
(PW) thickness, and internal dimensions at diastole and
systole (LVIDd and LVIDs, respectively) were measured.
LV fractional shortening [(LVIDd – LVIDs)/LVIDd] and
relative wall thickness [(IVS thickness + PW thickness)/
LVIDd] were calculated from the M-mode measurements.
Genetic and statistical analysis
Single nucleotide polymorphisms (SNPs, n = 1,701) in-
formative between the parental DBA/2J and MRL/MpJ
strains were genotyped in 80 SgcgMRL/D2F2-F4 Sgcg ani-
mals on the Illumina GoldenGate platform using the
Mutation Mapping and Developmental Analysis Panel
(MMDAP) [27] and the Mouse Universal Genotyping
Array (GeneSeek, Neogen Corp., Lansing, MI) [28]. R
package QTLRel was used to perform whole-genome
quantitative trait locus (QTL) mapping for each of the
membrane permeability and fibrosis phenotypes and
using sex as a covariate [29,30]. Significance thresholds
were determined by 1,000 permutation tests. The 1.5-
LOD drop support interval was calculated using
QTLRel. Tests of normality and other statistics were cal-
culated in Prism (GraphPad). Build 37.1 was used for
genomic analysis.
For HOP and dye uptake assays, data were analyzed by
one-way, unpaired ANOVA with parametric methods
followed by the Tukey multiple comparison post-test
(Prism, Graphpad), and p < 0.05 was considered signifi-
cant. Data from 197 Sgcg animals from an F3 intercross
between the DBA/2J and 129T2/SvEmsJ backgrounds
(SgcgD2/129 ) was compared to the SgcgMRL/D2cohort.
Results
A 50% contribution of the MRL background reduces
fibrosis in Sgcg mice
To assess the MRL contribution to muscular dystrophy,
we used the MRL/MpJ substrain since it contains a wild-
type fas allele [1]. We also used mice lacking γ-
sarcoglycan (Sgcg null) since these mice are a model of
limb girdle muscular dystrophy 2C [18] and on the
DBA/2J background have a more severe phenotype,
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MpJ mice were bred to Sgcg null and then interbred to
generate Sgcg null mice with a 50% MRL/MpJ and 50%
DBA/2J contribution. In Sgcg null mice, like all dys-
trophin complex-associated mutations, fibrosis and col-
lagen deposition is increased in the heart and muscle,
similar to what is seen in human patients with similar
mutations [18,31]. A 50% contribution from the MRL
background reduced fibrosis in Sgcg heart and muscles
(Figure 1). In Sgcg hearts, fibrosis was often seen grossly
as large patchy white areas and with the introduction of
the MRL background visible fibrosis was diminished so
that the hearts were indistinguishable from those of
wild-type mice (Additional file 1: Figure S1). Of all the
muscle groups analyzed, only diaphragm muscle retained
any visible fibrosis. Diaphragm muscle is the most con-
sistently damaged muscle in multiple mouse models, in-
cluding this model, and the mdx model of Duchenne
muscular dystrophy [32]. Therefore, it is possible that
the degree of injury in this muscle overwhelms the heal-
ing properties of the MRL background.
We quantified fibrosis by measuring HOP content as
an indicator of collagen in SgcgD2 and SgcgMRL/D2 mus-
cles. SgcgMRL/D2 mice have significantly reduced fibrosis
compared to SgcgD2 mice (Figure 2). We also evaluatedFigure 1 The MRL genome suppresses fibrosis in the heart and
muscles of SgcgD2 mice. Sgcg mice lack the dystrophin-associated
protein, γ-sarcoglycan, and when in the DBA/2J (D2) background
have a more severe phenotype with enhanced membrane leak and
fibrosis [21]. A 50% contribution of the MRL genome, referred to as
SgcgMRL/D2, suppressed fibrosis in both heart and skeletal muscle.fibrosis in aged (32 week) animals and found a persistent
reduction in fibrosis in the SgcgMRL/D2 mice (Figure 2, di-
agonal bars). The 129T2/SvEmsJ strain was previously
shown to suppress the severity of muscle pathology in Sgcg
null mice [33]. In comparison, the MRL backgroundFigure 2 The MRL genome quantitatively reduces fibrosis in
Sgcg mice. Hydroxyproline (HOP) is a measure of fibrosis and is
represented on the y axis (mM/mg). In the heart, diaphragm and
quadriceps muscles, fibrosis is significantly (p < 0.001) reduced in
intercrossed SgcgMRL/D2 (D2/MRL) animals compared to Sgcg in the D2
(D2) background at 8 weeks. Fibrosis remains significantly (***p < 0.001)
reduced in SgcgMRL/D2 animals at the 32-week time point.
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ground (Figure 3). The MRL background dramatically
reduced fibrosis in the heart and abdominal muscles com-
pared to 129T2/SvEmsJ. The MRL background also sup-
pressed fibrosis more than the 129T2/SvEmsJ background
in the diaphragm and quadriceps muscles, but to a lesser
degree. This finding suggests that the phenotypically bene-
ficial genetic modifiers in the MRL genome may be more
potent than those in the 129T2/SvEmsJ genome.
The MRL background does not protect against membrane
leak
Disruption of the membrane-associated dystrophin com-
plex renders the sarcolemma unusually fragile, leading to
abnormal membrane leakage that is visualized by uptake of
the nonspecific vital tracer Evans blue dye [20]. Upon gross
inspection, the muscles from the SgcgMRL/D2 mice displayed
high levels of dye uptake, comparable to what was observed
in the parental Sgcg mice (Additional file 1: Figure S1). On
a microscopic level, dye-positive cells were readily detect-
able in SgcgMRL/D2 muscle and heart (Figure 4). Evans blue
dye levels were measured in multiple muscle groups and
were not significantly different between SgcgMRL/D2 and
SgcgD2 muscles for quadriceps, triceps, gastrocnemius/
soleus, gluteus and abdominals muscle groups (Figure 5).
We also measured dye uptake in older animals at 32 weeks
to assess disease progression. At 32 weeks, the skeletal
muscles continued to show comparable levels of membrane
leak as what was seen at 8 weeks (Figure 5). The gluteus/
hamstring group of muscles showed an increased of dye
uptake compared to the 8-week animals. This increase was
not seen for other muscle groups.Figure 3 The reduction of fibrosis in intercrossed Sgcg animals is spe
fibrosis and is represented on the y axis (mM/mg). Fibrosis is significantly r
(*p = 0.041) and abdominal muscles (p < 0.001) of Sgcg animals intercrosse
D2/129 background.We compared suppression of dye uptake by the MRL
background to that induced by the 129T2/SvEmsJ back-
ground in Sgcg mice (Figure 6). The quadriceps and ab-
dominal muscles from Sgcg null mice with a contribution
from the 129T2/SvEmsJ background showed increased
membrane leak compared to Sgcg mice with an MRL con-
tribution. However, the triceps muscle group from the
MRL background showed increased dye uptake, and the
gluteus/hamstring muscle group showed no significant dif-
ference. Thus, there was no consistent suppression of
membrane leakiness by the MRL strain.
The MRL genome may promote skeletal muscle
regeneration
The MRL background is thought to exert part of its effect
by promoting regeneration [34]. We examined embryonic
myosin heavy chain (eMHC) expression as a reflection of
regeneration. SgcgMRL/D2 muscle shows patchy areas with a
qualitative increase in eMHC-positive fibers compared to
Sgcg (Figure 7), and wild-type muscle showed no eMHC
positive fibers (data not shown). In dystrophic skeletal
muscle, ongoing regeneration is thought to offset degener-
ation. Consistent with this, eMHC-positive regions were
also positive for Evans blue dye uptake, indicative of
muscle damage. We also evaluated phosphorylated histone
3 (PH3) as a reflection of mitotic index. No clear differ-
ences for PH3 staining were seen between SgcgMRL/D2 and
Sgcg muscle. Regenerating skeletal muscle, whether from
trauma or muscular dystrophy, is identified by the presence
of myofibers with centrally positioned nuclei. In muscular
dystrophy, ongoing regeneration is also marked by
increased fiber size variability. SgcgMRL/D2 mice have ancific to the MRL genome. Hydroxyproline (HOP) is a measure of
educed in the heart (***p < 0.001), diaphragm (p < 0.001), quadriceps
d in the D2/MRL background compared to those intercrossed in the
Figure 4 Membrane leak is not corrected by the presence of
the MRL genome in Sgcg heart and muscle. Evans blue dye is
found in cardiomyocytes and skeletal myofibers reflecting
membrane leakiness. Dye uptake occurs in patchy pattern
throughout the heart and muscle and is seen as opacified cells that
fluoresce red. Nuclei are shown in blue and dystrophin in green.
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phragm muscle compared to SgcgD2 mice (Figure 7). These
same muscles also showed increased fiber size variability
when there is a contribution from the MRL background.
These data are consistent with a model in which favorable
matrix remodeling may support enhanced regeneration.
We also assessed apoptosis using a TUNEL assay and
caspase 3 staining and again found no differences be-
tween SgcgMRL/D2 and Sgcg muscle, suggesting that
gross differences in programmed cell death are unlikely
to account for the improved healing of the MRL strain
(Additional file 1: Figure S2). We also characterized
whether T cell infiltration or macrophage infiltration
differed qualitatively between SgcgMRL/D2 and Sgcg
muscle, but we found no clear differences between
SgcgMRL/D2 and Sgcg muscle, suggesting other features
contribute to the MRL background’s effect on muscular
dystrophy (Additional file 1: Figure S2).Improved cardiac function from a 50% contribution of
the MRL background
We performed 2D and M mode echocardiography on
SgcgMRL/D2 and SgcgD2 mice at 12 weeks of age. Both frac-
tional shortening and the left ventricular ejection fraction
were significantly reduced in SgcgD2 mice, indicating that
the increased fibrosis impairs cardiac function (Table 2).
Fractional shortening and the left ventricular ejection frac-
tion were similar between SgcgMRL/D2 andWTMRL/D2 mice,
consistent with improved function mediated by 50% of the
MRL genome. Wall thickness was also increased in Sgcg
mice compared to the wild type of the same background.
In contrast, wall thickness was not different between
SgcgMRL/D2 andWTMRL/D2 mice.Chromosome 2 associates with reduced fibrosis Sgcg
heart and diaphragm muscle
We conducted a genome-wide scan using markers that
were informative in the two parental strains DBA/2J and
MRL/MpJ (Figure 8). QTLRel was used to identify
regions of association; this analysis takes into account
the relatedness of individual animals in the cohort
[29,30]. A region on chromosome 2 was identified that
associated with fibrosis in the heart. The 1.5-LOD drop
interval of this region spans from 64.8008−73.1758 cM
in mouse genome build 37.1. This same region was also
associated with fibrosis in the diaphragm muscle and
also for fibrosis in the abdominal muscles. It should be
noted that the significance of these associations is sug-
gestive (p < 0.63) when using the stringent QTLRel ana-
lysis. However, the overlapping intervals found in heart,
diaphragm and abdominal muscles provide additional
support that this interval modifies fibrosis.Ltbp4 polymorphism does not account for the MRL
healing properties
The DBA/2J strain contains an insertion/deletion poly-
morphism within the Ltbp4 gene [21] that modifies both
membrane permeability and fibrosis, as two independent
traits, in Sgcg muscular dystrophy. Ltbp4 encodes latent
TGFβ-binding protein 4, and TGFβ proteins have been
extensively linked to fibrosis in many disease states in-
cluding muscular dystrophy [35,36]. Most murine
strains, including the MRL/MpJ strain used here, contain
the protective Ltbp4 allele with an additional 12 amino
acids inserted in exon 12. Because the SgcgMRL/D2 cohort
used here contained both the protective (LtbpI allele)
and the disease-enhancing allele (Ltbp4D), we tested
whether Ltbp4 genotype correlated with fibrosis in the
SgcgMRL/D2 cohort. Table 3 shows that neither membrane
permeability nor fibrosis is correlated with the Ltbp4
genotype in the SgcgMRL/DBA2J cohort. Therefore, Ltbp4
does not account for the suppressive effect of the MRL
Figure 5 The MRL genome does not significantly reduce membrane damage in Sgcg muscle. Evans blue dye uptake is a measure of
membrane damage and is represented on the y axis (absorbance/mg). In the quadriceps, triceps, abdominal and gastrocnemius/soleus muscles,
membrane damage is not significantly different between SgcgD2 animals and intercrossed SgcgMRL/D2 animals at both the 8- and 32-week time
points. In the gluteus/hamstring muscles, membrane damage is significantly (**p < 0.01) increased at the 32-week time point in intercrossed Sgcg
MRL/D2 animals compared to the 8-week time point.
Figure 6 The MRL genome has a variable ability to reduce membrane leak in muscular dystrophy compared to the 129T2/SvEmsJ
strain. Evans blue dye uptake was measured in multiple muscle groups represented on the y axis (absorbance/mg). Membrane damage is
reduced in the quadriceps (**p = 0.0053) and abdominal (**p = 0.0012) muscles of intercrossed SgcgD2/MRL animals compared to intercrossed
SgcgD2/129 mice. Membrane damage is increased in the triceps muscle (*p = 0.0298) of intercrossed SgcgMRL/D2 animals. There is no difference in
membrane damage in the gluteus/hamstring muscle.
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Figure 7 Regeneration may be enhanced in the MRL background. Embryonic myosin heavy chain (eMHC) staining was increased in
SgcgMRL/D2 compared to Sgcg muscle, and eMHC fibers were seen in areas where dye uptake was seen. However, phosphorylated histone 3 (PH3),
a marker of mitotic index, was not increased in SgcgMRL/D2 compared to Sgcg muscle. Skeletal muscle central nucleation and fiber size variability
are enhanced by the MRL background. SgcgMRL/D2 muscle demonstrated an increase in centrally nucleated fibers compared to SgcgD2 mice. Fiber
size variability was reflected in the coefficient of variability of fiber diameter measurements. The solid line indicates significance (p < 0.05). These
data support that the MRL exerts its effect in skeletal muscle, at least in part, by promoting regeneration.
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Discussion
The MRL genome protects against fibrosis but not
membrane leak
Mutations in the dystrophin or sarcoglycan genes share a
common pathological mechanism characterized by disrup-
tion of the plasma membrane of cardiomyocytes and skel-
etal myofibers. Membrane leak is an early step in the
pathological process while fibrosis is thought to be a sec-
ondary response. Our study suggests that there are genetic
pathways that target fibrosis without altering the sarco-
lemmal leak properties. In the heart, reduced fibrosis was
correlated with functional benefit, although cardiac func-
tion may be improved from both cardiac intrinsic as well
as cardiac extrinsic features. For example, improved skel-
etal muscle function may contribute to improved cardiac
function, particularly when considering the contribution
of the respiratory musculature.Table 2 Cardiac function in Sgcg mice
Fractional shortening
SgcgD2(n = 4) 33.87 ± 4.80a
WTD2 (n = 5) 44.58 ± 7.65a
SgcgMRL/D2 (n = 5) 46.00 ± 14.4
WTMRL/D2 (n = 5) 48.37 ± 11.21
ap = 0.046.The MRL strain typically shows the improved healing
capability in its first 2–6 months of life. After 6 months of
age, wild-type MRL mice develop autoimmune disorders;
it is for this reason that we conducted studies using a 50%
contribution of the MRL strain. Quantitative trait mapping
has been used to define many different genetic regions
associated with the healing properties [14]. The auto-
immune properties have been genetically separated from
the healing properties since the four to six different “auto-
immune” genetic loci do not overlap with those associated
with improved healing. In our studies, only 50% of the
MRL genome was capable of suppressing fibrosis and im-
proving function. In the course of these studies, we never
identified a single SgcgMRL/D2 animal that had markedly ele-
vated fibrosis. This stands in contrast to what is normally
observed in the Sgcg animals where outliers with markedly
elevated fibrosis are often seen. The maximum values for
fibrosis in SgcgMRL/D2 mice were all well below what was
measured in SgcgD2 mice. This is consistent with multiple,
dominant genetic loci imparting the improved healing cap-
abilities, similar to what has been observed for the ear hole
repair properties in the MRL strain [37]. The finding that
improvement persists in the SgcgMRL/D2 mice, with almost
complete suppression of fibrosis at 32 weeks, suggests that
a persistent healing effect can arise from the MRL strain.
Chromosome 2 candidate genes
When considering the overlapping region on chromo-
some 2 from the heart, diaphragm and abdominal
Figure 8 Fibrosis in the heart, diaphragm and abdominal
muscles is modified by a locus on chromosome 2. Genome-wide
association was examined for fibrosis in SgcgMRL/D2 progeny in the
(A) cardiac muscle (n = 65), (B) diaphragm (n = 78) and (C)
abdominal muscle (n = 78). Chromosomes are plotted on the x axis,
and the informative SNPs tested (n = 1,707) are displayed as open
circles that alternate color by chromosome; LOD scores are
represented on the y axis. Overlapping regions on chromosome 2
showed suggestive (p < 0.63) association with fibrosis in heart,
diaphragm and abdominal muscle.
Table 3 Ltbp4 genotype in SgcgMRL/D2 mice
Dye uptake Fibrosis
Ltbp4D/D (n = 14) 3.90 ± 0.83 6.00 ± 1.81
Ltbp4D/I (n = 34) 4.18 ± 0.84 8.05 ± 3.02
LtbpI/I (n = 47) 4.00 ± 0.85 6.64 ± 2.15
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There are additional predicted and unnamed genes and
genes encoding olfactory receptors that are not consid-
ered likely candidates. Within the interval is Jag1, encod-
ing jagged the ligand for the Notch receptor. Loss of
function of Notch 3 leads to muscle hyperplasia, espe-
cially when subjected to repetitive injury [38]. Ex vivo
activation of Notch signaling helps maintain donor cell
engraftment during myoblast transfer [39]. Another gene
linked to growth and healing in the interval is Bmp2-en-
coding bone morphogenetic protein 2. The BMPs medi-
ate musculoskeletal regeneration [40], and given the
MRL background effect on multiple cells and tissues,
BMP2 is well positioned to contribute to the MRL
superhealing response. That said, this chromosome 2
interval has not previously been linked to other MRL
healing properties. The strict criteria imposed by the
QTLRel algorithm makes it unlikely that these results
derive from relatedness of animals within the cohort.
Cardiac injury and repair in the MRL strain
The ability of the heart to recover after injury has been
studied in the MRL strain using cryoinjury, left anterior
descending ligation and ischemia reperfusion methods
[5,6,8-10,14,15]. However, scar reduction has been noted
after some forms of injury while not after others. In
common to all these studies is an acute injury model
where a normal heart was substantially damaged in a
single setting. The MRL’s ability to heal the heart may be
limited such that larger amounts of injury may be insur-
mountable, as proposed by Naseem [6]. Our data sup-
port that lower, although persistent, levels of injury can
be managed by the MRL strain where there is significant
reduction in fibrosis and a corresponding functional im-
provement in cardiac function.
Mechanisms for MRL healing
A number of mechanisms likely act in concert to achieve
suppression of fibrosis and improvement of function. In
skeletal muscle, where muscle stem cells robustly regen-
erate muscle after injury, there is indirect evidence of
enhanced regeneration. Specifically, there is an increase
in centrally nucleated myofibers, which is thought to re-
flect enhanced myoblast fusion. However, our data do
not distinguish whether the MRL background exerts its
effect on muscle regenerative cells, or by creating a more
supportive extracellular matrix or both. MRL animals
heal with embryonic characteristics with enhanced blas-
tema formation and metabolic and gene expression fea-
tures consistent with an earlier developmental state [41].
Altered protease expression has also been noted in the
MRL mouse in response to damage [5]. Recent work
characterizing the immune infiltrate in muscular dys-
trophy found that reducing osteopontin was effective at
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matrix-associated modifications that can modulate
muscle fibrosis and function.
Conclusions
Herein the MRL background was shown to reduce fibrosis
in a chronic model of muscular dystrophy and cardiomy-
opathy, the Sgcg mouse. Although membrane leak was still
evident in Sgcg mice sharing a portion of the MRL gen-
ome, the reduction in fibrosis was associated with
improved cardiac function. The identification of gene(s)
from the MRL genome will help identify pathways import-
ant for chronic repair of myopathic processes.
Additional file
Additional file 1: Figure S1. Shown are gross images from Sgcg vs.
SgcgMRL/D2 mice. Evans blue dye uptake could be readily seen in the
quadriceps and diaphragm muscles and did not appear grossly altered
by the presence of the MRL background. In contrast, fibrosis was visually
reduced in the quadriceps and heart of SgcgMRL/D2 compared to Sgcg
mice. The diaphragm muscle retained evidence of fibrosis in SgcgMRL/D2,
but the white stripes of fibrosis were smaller, and intact diaphragm
muscle was still evident compared to the near total replacement of
diaphragm muscle in Sgcg mice. Figure S2. Shown is staining for
apoptosis with TUNEL and caspase indicating no gross differences
between Sgcg and SgcgMRL/D2 muscle. CD3 and MAC1 staining to
examine T cell and macrophage infiltrate also did not appear grossly
altered by the presence of the MRL background.
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